The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $29.91

Today's change-0.44 -1.45%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Bio-Reference Laboratories Inc

Nasdaq: BRLI
Last

(U.S.) $29.91

Today's change-0.44 -1.45%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Bio-Reference Laboratories Inc down (U.S.)$0.44

Bio-Reference Laboratories Inc closed lower Friday, dropping (U.S.)$0.44 or 1.45% to (U.S.)$29.91. Over the last five days, shares have gained 8.29% and 17.11% year to date. Shares have outperformed the S&P 500 by 4.41% during the last year.

Key company metrics

  • Open(U.S.) $30.27
  • Previous close(U.S.) $30.35
  • High(U.S.) $30.77
  • Low(U.S.) $29.72
  • Bid / Ask-- / --
  • YTD % change+17.11%
  • Volume743,527
  • Average volume (10-day)371,747
  • Average volume (1-month)252,912
  • Average volume (3-month)206,911
  • 52-week range(U.S.) $24.13 to (U.S.) $34.00
  • Beta0.85
  • Trailing P/E17.82×
  • P/E 1 year forward14.96×
  • Forward PEG1.45×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.68
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+5.62%

Based on its net profit margin of 5.62%, Bio-Reference Laboratories Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Healthcare Facilities
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJul 31, 201407/31/2014Apr 30, 201404/30/2014Jan 31, 201401/31/2014Oct 31, 201310/31/2013
Revenue222201181192
Total other revenue--------
Total revenue222201181192
Gross profit102897285
Total cost of revenue120113109107
Total operating expense194182175172
Selling / general / administrative73686564
Research & development--------
Depreciation / amortization1211
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income2819620
Interest income (expense), net non-operating-1-1-1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax2718520
Income after tax1510311
Income tax, total12829
Net income1510311
Total adjustments to net income--------
Net income before extra. items1510311
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1510311
Inc. avail. to common incl. extra. items1510311
Diluted net income1510311
Dilution adjustment--------
Diluted weighted average shares28282828
Diluted EPS excluding extraordinary itemsvalue per share0.550.370.110.40
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share0.550.370.110.40